Evidence map›Paper›PMID 24928034›Full record

ArticleVirology2014

Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells.

Adriana Forero, Kevin D McCormick, Frank J Jenkins, Saumendra N Sarkar

Open access · greenAbstract read
In one paragraph

Article in Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  2. Article
  3. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functionalProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Adriana ForeroCancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, USA.
Kevin D McCormickCancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, USA.
Frank J JenkinsDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Saumendra N SarkarCancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, USA. Electronic address: saumen@pitt.edu.
UPMC Hillman Cancer Center · USUniversity of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Novel Modifiers of Toll-like and RIG-like Receptor SignalingU24AI082673 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SARKAR, SAUMENDRA N · 2009 to 2013
$1.5M
NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NIAID NIH HHS AI082673NIAID NIH HHS U24 AI082673
6 · The paper itself

Abstract

Primary effusion lymphoma (PEL), associated with the latent infection by KSHV, constitutively expresses interferon-regulatory factor 4 (IRF4). We recently showed that IRF4 differentially regulates expression of cellular interferon-stimulated genes (ISGs) and viral genes (Forero et al., 2013). Here, using inducible IRF4 knockdown, we demonstrate that IRF4 silencing results in enhanced transcription of KSHV replication transactivator RTA. As a result viral transcription is increased leading to virus reactivation. Taken together, our results show that IRF4 helps maintain the balance between latency and KSHV reactivation in PEL cells.

Indexed as

Cell LineDown-RegulationGene SilencingHerpesvirus 8, HumanHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsVirus LatencyInterferon Regulatory Factor-4Interferon Regulatory FactorsInterferon regulatory factor 4Kaposi׳s sarcoma-associated herpesvirusPrimary effusion lymphoma

Identifiers

PMID24928034
PMCPMC4058074
OpenAlexW2094607954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.